{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T12:27:00Z","timestamp":1759580820625,"version":"3.37.3"},"reference-count":9,"publisher":"American Society of Hematology","issue":"21","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,5,24]]},"DOI":"10.1182\/blood-2018-04-841908","type":"journal-article","created":{"date-parts":[[2018,5,24]],"date-time":"2018-05-24T12:30:46Z","timestamp":1527165046000},"page":"2278-2280","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":3,"title":["The future of kinase inhibitors for DLBCL?"],"prefix":"10.1182","volume":"131","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3044-9840","authenticated-orcid":false,"given":"Sarah E. M.","family":"Herman","sequence":"first","affiliation":[{"name":"National Institutes of Health"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"21","key":"2019111905410777800_B1","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1182\/blood-2017-10-809210","article-title":"Pan-SRC kinase inhibition blocks B-cell receptor oncogenic signaling in non-Hodgkin lymphoma","volume":"131","author":"Battistello","year":"2018","journal-title":"Blood"},{"issue":"12","key":"2019111905410777800_B2","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1084\/jem.194.12.1861","article-title":"Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells","volume":"194","author":"Davis","year":"2001","journal-title":"J Exp Med"},{"issue":"8","key":"2019111905410777800_B3","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/nm.3884","article-title":"Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma","volume":"21","author":"Wilson","year":"2015","journal-title":"Nat Med"},{"issue":"8","key":"2019111905410777800_B4","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1182\/blood-2016-10-747303","article-title":"Tonic B-cell receptor signaling in diffuse large B-cell lymphoma","volume":"130","author":"Havranek","year":"2017","journal-title":"Blood"},{"issue":"20","key":"2019111905410777800_B5","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"21","key":"2019111905410777800_B6","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.1777.1777","article-title":"Clinical safety and activity in a phase 1 study of CAL-101, an isoform- selective inhibitor of phosphatidylinositol 3-kinase P110\u03b4, in patients with relapsed or refractory non-Hodgkin lymphoma [abstract]","volume":"116","author":"Kahl","year":"2010","journal-title":"Blood"},{"issue":"20","key":"2019111905410777800_B7","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1182\/blood-2015-12-683516","article-title":"Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL","volume":"127","author":"Barr","year":"2016","journal-title":"Blood"},{"key":"2019111905410777800_B8","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1182\/asheducation-2017.1.284","article-title":"Tailoring front-line therapy in diffuse large B-cell lymphoma: who should we treat differently?","volume":"2017","author":"Davies","year":"2017","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"4","key":"2019111905410777800_B9","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1586\/14737140.2015.1009042","article-title":"Emerging drugs for diffuse large B-cell lymphoma","volume":"15","author":"Mondello","year":"2015","journal-title":"Expert Rev Anticancer Ther"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/131\/21\/2278\/1468620\/blood841908.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/131\/21\/2278\/1468620\/blood841908.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T05:42:17Z","timestamp":1574142137000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/131\/21\/2278\/37143\/The-future-of-kinase-inhibitors-for-DLBCL"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,24]]},"references-count":9,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2018,5,24]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2018-04-841908","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"type":"print","value":"0006-4971"},{"type":"electronic","value":"1528-0020"}],"subject":[],"published":{"date-parts":[[2018,5,24]]}}}